drugset / Trial / NCT05129280
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy dose-escalation and dose expansion study of RO7444973.The aim of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RO7444973 in participants with unresectable and/or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive, solid tumors, carrying the HLA-A\*02:01 allele.
Timeline
- Start
- 2022-01-25
- Primary completion
- 2023-07-12
- Completion
- 2023-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RO7444973 | Unknown | — | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | 12 mg/kg | Intravenous |